Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Impaired Glucose Metabolism Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Cassia Cinnamon for Glucose Uptake in Young Women

NCT00951639
View directory record Official record
Conditions
Insulin Resistance, Impaired Glucose Tolerance, Prediabetes
Interventions
Cassia cinnamon, 50 minutes exercise, Cellulose Powder
Dietary Supplement · Procedure
Lead sponsor
Baylor University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

NCT00886626
View directory record Official record
Conditions
Obesity, Morbid
Interventions
Exenatide
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance

NCT00108615
View directory record Official record
Conditions
Glucose Metabolism Disorders, Diabetes
Interventions
Metformin, Pioglitazone, CT scans, Oral glucose tolerance test
Drug · Radiation · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
35 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2008 · Synced Oct 10, 2026, 2:09 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Red Blood Cell Survival on a Commonly Used Diabetes Lab Test-HbA1c

NCT01204216
View directory record Official record
Conditions
Diabetes Mellitus, Impaired Fasting Glucose, Prediabetes
Interventions
Re-infusion of biotin labeled cells, Diabetes education/diabetes medication adjustment
Biological · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sucralose, Stevia, Gut Microbiome and Glucose Metabolism

NCT02800707
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Sucralose, Stevia
Other
Lead sponsor
University of Minnesota
Other
Eligibility
35 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

NCT01478399
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PB1023 Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults

NCT02335021
View directory record Official record
Conditions
Impairment of Oral Perception, Insulin Resistance
Interventions
Sucralose, Sucrose, Sucralose + maltodextrin, Sucralose + Sucrose
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
23 Years to 45 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Macronutrient Effects on Alzheimer's Disease (MEAL-2)

NCT02463084
View directory record Official record
Conditions
Prediabetic State, Insulin Resistance, Middle Age, Prehypertension, Mild Cognitive Impairment
Interventions
Low Diet, High Diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
45 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

NCT01620489
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
53
States / cities
Concord, California • La Jolla, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 10, 2026, 2:09 PM EDT
Withdrawn Not applicable Interventional

Isoleucine Addition Treatment Effects in a Controlled Diet Study

NCT07329088
View directory record Official record
Conditions
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Metabolic Syndrome (MetS), Obesity & Overweight
Interventions
L-Isoleucine, Low-isoleucine diet
Dietary Supplement · Other
Lead sponsor
Jean L. Fry
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lantus in Prediabetes

NCT00348972
View directory record Official record
Conditions
Hyperglycemia, Diabetes Mellitus
Interventions
Lantus® (insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 6, 2006 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation

NCT00470262
View directory record Official record
Conditions
Metabolic Syndrome X, Prediabetic State
Interventions
Fenofibrate 145mg PO QD, Pioglitazone 45 mg PO QD
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

NCT00673790
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol with concomitant losartan or lisinopril, HCTZ with concomitant losartan or lisinopril, Placebo with concomitant losartan or lisinopril
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
88
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 10, 2026, 2:09 PM EDT
Completed No phase listed Observational

Real-world Aliskiren Use in Diabetic Patients

NCT01393860
View directory record Official record
Conditions
Diabetes, Hypertension
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 10, 2026, 2:09 PM EDT
Recruiting Not applicable Interventional

Feasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL)

NCT06640179
View directory record Official record
Conditions
Kidney Transplant, Overweight or Obese Adults, Glucose Control
Interventions
Standard medical care, Monitoring Contacts, Behavioral Sessions, Diet, Physical Activity
Other · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Not applicable Interventional Results available

Improving Medication Adherence in Older African Americans With Diabetes

NCT02174562
View directory record Official record
Conditions
Type 2 Diabetes, Mild Cognitive Impairment
Interventions
Primary Care-Occupational Therapy, Enhanced Usual Care
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
60 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

NCT00663260
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
34
States / cities
Mesa, Arizona • Fresno, California • Greenbrae, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 10, 2026, 2:09 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

NCT07793929
View directory record Official record
Conditions
End Stage Renal Disease, Renal Impairment, Obesity, Overweight
Interventions
Ribupatide
Drug
Lead sponsor
Kailera
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

NCT03242252
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
51
States / cities
Birmingham, Alabama • Guntersville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Not applicable Interventional

Nonvisual Foot Inspection for People With Visual Impairment

NCT01822717
View directory record Official record
Conditions
Diabetes, Visual Impairment
Interventions
Nonvisual foot inspection, Usual Care
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 10, 2026, 2:09 PM EDT
Terminated Phase 3 Interventional

Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes

NCT00325650
View directory record Official record
Conditions
Prediabetic State
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
2,420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 10, 2026, 2:09 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effects of an Obesogenic Lifestyle in Recreationally Active, Young Adults

NCT05912348
View directory record Official record
Conditions
Insulin Resistance, Impaired Glucose Tolerance, Obesity, Metabolic Disturbance
Interventions
Low Physical Activity and Added Carbohydrate Group, Low physical Activity Control, High Physical Activity and Added Carbohydrate Group
Behavioral
Lead sponsor
University of New Hampshire
Other
Eligibility
18 Years to 30 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Durham, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.

NCT00938158
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Anniston, Alabama • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 10, 2026, 2:09 PM EDT